185 related articles for article (PubMed ID: 37511593)
1. Investigation of Clinically Significant Molecular Aberrations in Patients with Prostate Cancer: Implications for Personalized Treatment, Prognosis and Genetic Testing.
Fountzilas E; Kouspou M; Eliades A; Papadopoulou K; Bournakis E; Goussia A; Tsiatas M; Achilleos A; Tsangaras K; Billioud G; Loizides C; Lemesios C; Kypri E; Ioannides M; Koumbaris G; Levva S; Vakalopoulos I; Paliouras A; Pervana S; Koinis F; Bumci R; Christopoulou A; Meditskou S; Psyrri A; Boukovinas I; Visvikis A; Karavasilis V; Koukoulis GK; Kotsakis A; Giannakis D; Fountzilas G; Patsalis PC
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511593
[TBL] [Abstract][Full Text] [Related]
2. The Prognostic Significance of Homologous Recombination Repair Pathway Alterations in Metastatic Hormone Sensitive Prostate Cancer.
Lee AM; Saidian A; Shaya J; Nonato T; Cabal A; Randall JM; Millard F; Stewart T; Rose B; Tamayo P; McKay RR
Clin Genitourin Cancer; 2022 Dec; 20(6):515-523. PubMed ID: 35871039
[TBL] [Abstract][Full Text] [Related]
3. Homologous recombination repair gene mutations in Chinese localized and locally advanced prostate cancer patients.
Jiang X; Hu X; Gu Y; Li Y; Jin M; Zhao H; Gao R; Huang Z; Lu J
Pathol Res Pract; 2021 Aug; 224():153507. PubMed ID: 34102435
[TBL] [Abstract][Full Text] [Related]
4. Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA.
Matsubara N; de Bono J; Olmos D; Procopio G; Kawakami S; Ürün Y; van Alphen R; Flechon A; Carducci MA; Choi YD; Hotte SJ; Korbenfeld E; Kramer G; Agarwal N; Chi KN; Dearden S; Gresty C; Kang J; Poehlein C; Harrington EA; Hussain M
Clin Cancer Res; 2023 Jan; 29(1):92-99. PubMed ID: 36318705
[TBL] [Abstract][Full Text] [Related]
5. DNA-Damage-Repair Gene Alterations in Genitourinary Malignancies.
Dariane C; Timsit MO
Eur Surg Res; 2022; 63(4):155-164. PubMed ID: 35944490
[TBL] [Abstract][Full Text] [Related]
6. Somatic and germline aberrations in homologous recombination repair genes in Chinese prostate cancer patients.
Liu Y; Jin B; Shen C; Gao X; Qi X; Ma M; Li H; Hao H; Tang Q; Yang K; Mi Y; Guan J; Feng X; He Z; Li H; Yu W
Front Oncol; 2023; 13():1086517. PubMed ID: 37064136
[TBL] [Abstract][Full Text] [Related]
7. Prognostic outlier genes for enhanced prostate cancer treatment.
Kim H; Skowronski J; Den RB
Future Oncol; 2017 Feb; 13(3):249-261. PubMed ID: 27728977
[TBL] [Abstract][Full Text] [Related]
8. Multi-Gene Next-Generation Sequencing Panel for Analysis of
Maloberti T; De Leo A; Coluccelli S; Sanza V; Gruppioni E; Altimari A; Zagnoni S; Giunchi F; Vasuri F; Fiorentino M; Mollica V; Ferrari S; Miccoli S; Visani M; Turchetti D; Massari F; Tallini G; de Biase D
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240284
[TBL] [Abstract][Full Text] [Related]
9. Clinical implications of homologous recombination repair mutations in prostate cancer.
Cresta Morgado P; Mateo J
Prostate; 2022 Aug; 82 Suppl 1():S45-S59. PubMed ID: 35657156
[TBL] [Abstract][Full Text] [Related]
10. Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.
de Bono JS; Mehra N; Scagliotti GV; Castro E; Dorff T; Stirling A; Stenzl A; Fleming MT; Higano CS; Saad F; Buttigliero C; van Oort IM; Laird AD; Mata M; Chen HC; Healy CG; Czibere A; Fizazi K
Lancet Oncol; 2021 Sep; 22(9):1250-1264. PubMed ID: 34388386
[TBL] [Abstract][Full Text] [Related]
11. Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
Antonarakis ES; Lu C; Luber B; Liang C; Wang H; Chen Y; Silberstein JL; Piana D; Lai Z; Chen Y; Isaacs WB; Luo J
Eur Urol; 2018 Aug; 74(2):218-225. PubMed ID: 29439820
[TBL] [Abstract][Full Text] [Related]
12. Bringing Prostate Cancer Germline Genetics into Clinical Practice.
Das S; Salami SS; Spratt DE; Kaffenberger SD; Jacobs MF; Morgan TM
J Urol; 2019 Aug; 202(2):223-230. PubMed ID: 30730411
[TBL] [Abstract][Full Text] [Related]
13. Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing.
Giri VN; Hegarty SE; Hyatt C; O'Leary E; Garcia J; Knudsen KE; Kelly WK; Gomella LG
Prostate; 2019 Mar; 79(4):333-339. PubMed ID: 30450585
[TBL] [Abstract][Full Text] [Related]
14. Targeting DNA Repair Defects for Precision Medicine in Prostate Cancer.
Athie A; Arce-Gallego S; Gonzalez M; Morales-Barrera R; Suarez C; Casals Galobart T; Hernandez Viedma G; Carles J; Mateo J
Curr Oncol Rep; 2019 Mar; 21(5):42. PubMed ID: 30919167
[TBL] [Abstract][Full Text] [Related]
15. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer.
Leyten GH; Hessels D; Jannink SA; Smit FP; de Jong H; Cornel EB; de Reijke TM; Vergunst H; Kil P; Knipscheer BC; van Oort IM; Mulders PF; Hulsbergen-van de Kaa CA; Schalken JA
Eur Urol; 2014 Mar; 65(3):534-42. PubMed ID: 23201468
[TBL] [Abstract][Full Text] [Related]
16. Early-onset metastatic and clinically advanced prostate cancer is a distinct clinical and molecular entity characterized by increased TMPRSS2-ERG fusions.
Chalmers ZR; Burns MC; Ebot EM; Frampton GM; Ross JS; Hussain MHA; Abdulkadir SA
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):558-566. PubMed ID: 33420417
[TBL] [Abstract][Full Text] [Related]
17. Genetic testing for hereditary prostate cancer: Current status and limitations.
Zhen JT; Syed J; Nguyen KA; Leapman MS; Agarwal N; Brierley K; Llor X; Hofstatter E; Shuch B
Cancer; 2018 Aug; 124(15):3105-3117. PubMed ID: 29669169
[TBL] [Abstract][Full Text] [Related]
18. Drug-gene Interaction Screens Coupled to Tumor Data Analyses Identify the Most Clinically Relevant Cancer Vulnerabilities Driving Sensitivity to PARP Inhibition.
Jamal K; Galbiati A; Armenia J; Illuzzi G; Hall J; Bentouati S; Barrell D; Ahdesmäki M; ; O'Connor MJ; Leo E; Forment JV
Cancer Res Commun; 2022 Oct; 2(10):1244-1254. PubMed ID: 36969741
[TBL] [Abstract][Full Text] [Related]
19. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.
Beltran H; Yelensky R; Frampton GM; Park K; Downing SR; MacDonald TY; Jarosz M; Lipson D; Tagawa ST; Nanus DM; Stephens PJ; Mosquera JM; Cronin MT; Rubin MA
Eur Urol; 2013 May; 63(5):920-6. PubMed ID: 22981675
[TBL] [Abstract][Full Text] [Related]
20. An Emerging Landscape for Canonical and Actionable Molecular Alterations in Primary and Metastatic Prostate Cancer.
Dawson NA; Zibelman M; Lindsay T; Feldman RA; Saul M; Gatalica Z; Korn WM; Heath EI
Mol Cancer Ther; 2020 Jun; 19(6):1373-1382. PubMed ID: 32220973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
